Agenus Botensilimab/Balstilimab Data Update in Sarcomas Selected for Oral Presentation at ESMO 2023Business Wire • 07/28/23
ESMO GI Data: Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal CancerBusiness Wire • 06/30/23
Agenus to Present at the American Society of Clinical Oncology 2023 Annual MeetingBusiness Wire • 04/26/23
Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal CancerBusiness Wire • 04/17/23
Agenus' Botensilimab in Combination with Balstilimab Shows 33% Durable Responses in Ovarian CancerBusiness Wire • 03/27/23